Who Will Be the Second Domestic Anti-depressant Innovative Drug?

In the field of depression treatment, domestic emerging innovative drugs are gradually attracting widespread attention. In recent years, domestic pharmaceutical enterprises have been actively engaged in the research and development of new anti-depressant drugs, aiming to break the long-standing market dominance of imports and generic drugs.

It is worth mentioning that in November 2022, Lvye Pharmaceutical successfully developed the first domestically developed anti-depressant new drug - sodium hydrogen torudilafen fumarate tablets. The drug became China's first domestically developed chemical medicine 1st-class innovative drug for the treatment of depression. This groundbreaking achievement has opened a new chapter in the development of domestic anti-depressant new drugs.

In addition to Lvye Pharmaceutical's torudilafen, there are other promising anti-depressant new drugs under development in China. For example, Jibei Pharmaceutical's JJH201501 is currently undergoing Phase III clinical trials. The drug is a novel multi-receptor action mechanism anti-depressant with superior safety performance. In addition, Huahai Pharmaceutical's hydroxypiperidone and Haosen Pharmaceutical's HS-10353, among other research products, also display different innovative mechanisms.

It is expected that with the continuous research and promotion of these domestic new drugs, the market landscape of anti-depressant drugs in China will usher in new changes in the future. Domestic innovative drugs will play a more important role in this field, providing more and more effective treatment options for depression patients. As for who will become the second domestic anti-depressant new drug, the industry is closely watching and full of expectations.